Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — DEEPctMUT: Tumor-naïve ctDNA with deep learning
PMID: 42332784 | Genome Med | Methods/Validation
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Tumor-naïve ctDNA at 0.03% VAF sensitivity matching tumor-informed methods is a genuine step-change; open-source Nextflow adds reproducibility |
| Clinical Relevance | 8 | Direct MRD monitoring application; 100% pre-surgical CRC sensitivity vs. 50% for commercial comparator is striking, but validation is single-cancer-type |
| Population Reach | 8 | MRD monitoring is relevant across all solid tumor types; CRC alone affects millions globally |
| Implementation Speed | 7 | Open-source pipeline lowers adoption barrier; lab validation required before clinical deployment |
| Evidence Strength | 7 | Methods/validation study with head-to-head comparator (Roche Avenio) is strong; single-institution, single cancer type is a limitation |
Key quantitative result: 100% sensitivity for pre-surgical CRC detection vs. 50% for Roche Avenio; VAF detection threshold of 0.03% External validation: Not yet independently replicated; internal validation only Main limitation: Single cancer type (CRC) validated; prospective clinical utility not yet demonstrated Equity implications: Open-source pipeline could democratize MRD testing in lower-resource settings that cannot afford proprietary platforms; benefit skewed toward institutions with bioinformatics capacity Evidence Maturity: Exploratory → moving toward Validated; landmark methods paper Triage score (OpenClaw): 9 | Phase 2 composite: 7.9
Article 2 — ctDNA MRD in stage III NSCLC with durvalumab
PMID: 42336205 | J Thorac Oncol | Prospective Multicenter
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | ctDNA MRD in NSCLC is an active field; demonstrating HR 2.95 in a PACIFIC-like cohort with serial sampling adds meaningful clinical data |
| Clinical Relevance | 8 | Direct stratification tool for high-risk relapsers; could trigger intensification or experimental arm enrollment |
| Population Reach | 7 | Stage III unresectable NSCLC is a large globally relevant population (~30% of all NSCLC at diagnosis) |
| Implementation Speed | 6 | Requires validated ctDNA assay infrastructure and prospective trial confirmation before changing standard of care |
| Evidence Strength | 7 | Prospective multicenter, 84 pts, 659 serial samples — good serial design; limited by sample size for definitive practice change |
Key quantitative result: HR 2.95 for disease progression in ctDNA-positive patients during durvalumab External validation: No independent replication yet; aligns with other ctDNA MRD data in lung cancer Main limitation: N=84 is insufficient to power definitive subgroup analyses or guide treatment changes Equity implications: Patients at well-resourced centers with ctDNA access will benefit first; access disparities in serial blood-based monitoring are significant Evidence Maturity: Validated (biomarker association); not yet Potentially Practice-Changing Triage score (OpenClaw): 9 | Phase 2 composite: 7.2
Article 3 — KRAS peptide vaccine + dual checkpoint blockade in mCRC
PMID: 42336869 | Nat Commun | Phase I Clinical Trial
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First-in-class combination of KRAS neoantigen vaccine + nivolumab/ipilimumab in mCRC; KRAS has been "undruggable" immunologically |
| Clinical Relevance | 7 | Phase I — proof of concept; efficacy data likely limited; mCRC with KRAS mutation represents ~40% of cases |
| Population Reach | 8 | KRAS mutations occur in ~40% of CRC and ~25% of NSCLC; if effective, population impact is enormous |
| Implementation Speed | 4 | Phase I; years from potential approval; manufacturing complexity for personalized vaccine |
| Evidence Strength | 6 | Phase I, likely small N, primary endpoint is safety; abstract_confidence is title_confirmed only (no efficacy data confirmed) |
Key quantitative result: Not disclosed in available metadata (title_confirmed only) External validation: None yet; first published trial of this specific combination Main limitation: Phase I = safety/tolerability primary; efficacy data preliminary; manufacturing scalability for peptide vaccine is major hurdle Equity implications: Personalized neoantigen vaccines will be expensive and complex to manufacture; likely to benefit wealthy healthcare systems first Evidence Maturity: Exploratory Triage score (OpenClaw): 9 | Phase 2 composite: 6.9
Article 4 — Stromal CD8+ TILs as negative predictive marker for chemo in ER+ breast cancer
PMID: 42337235 | Nat Commun | Retrospective Spatial Analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Spatial TIL analysis inverting conventional wisdom — high CD8+ TILs predicting chemo resistance (not benefit) in ER+ BC is counterintuitive and impactful |
| Clinical Relevance | 8 | Could directly spare patients from unnecessary chemotherapy; ER+ BC is the largest breast cancer subtype |
| Population Reach | 9 | ER+ breast cancer = ~70% of all breast cancer diagnoses; chemotherapy de-escalation is a major clinical need |
| Implementation Speed | 5 | Requires prospective validation; spatial TIL quantification not yet standard in clinical pathology |
| Evidence Strength | 6 | Retrospective; spatial methodology is rigorous but requires prospective confirmation; title_confirmed only |
Key quantitative result: High stromal CD8+ TIL density associated with chemotherapy resistance (specific HR/OR not available from metadata) External validation: Requires independent prospective cohort validation Main limitation: Retrospective design; spatial pathology not yet clinically standardized; unclear whether finding holds across chemotherapy regimens Equity implications: If validated, could spare patients in low-resource settings from toxic and costly chemotherapy; however spatial pathology infrastructure is concentrated in high-income settings Evidence Maturity: Exploratory Triage score (OpenClaw): 8 | Phase 2 composite: 7.2
Article 5 — Infigratinib in FGFR2-amplified gastric/GEJ cancer
PMID: 42337043 | Br J Cancer | Phase 2 Clinical Trial
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | FGFR inhibition in GEJ cancer is an established concept; Phase 2 data adds clinical weight to known biology |
| Clinical Relevance | 7 | FGFR2-amplified GEJ/gastric cancer is a validated biomarker-drug match; refractory setting has few options |
| Population Reach | 5 | FGFR2 amplification occurs in ~5–10% of GEJ adenocarcinomas; relatively small biomarker-selected population |
| Implementation Speed | 6 | Phase 2 single-arm; regulatory submission possible if results are strong; companion diagnostic required |
| Evidence Strength | 7 | Multicenter Phase 2 in biomarker-selected population is appropriate design; title_confirmed only, quantitative efficacy not confirmed |
Key quantitative result: Not disclosed in available metadata External validation: Aligns with other FGFR2-targeted trials (e.g., bemarituzumab data); no direct replication Main limitation: Single-arm Phase 2; small biomarker-selected population limits generalizability Equity implications: Requires FGFR2 testing which may not be available in lower-income settings; precision oncology access gap Evidence Maturity: Validated (biomarker rationale); Phase 2 clinical data pending full review Triage score (OpenClaw): 8 | Phase 2 composite: 6.4
Article 6 — Methionine-supplemented longevity diet: GH, GLP-1, FGF21, frailty
PMID: 42335894 | Cell Metab | Experimental/Translational
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Linking dietary methionine supplementation to GH/GLP-1/FGF21 axis in a longevity context is mechanistically novel |
| Clinical Relevance | 5 | Experimental/translational; frailty reduction is promising but clinical translation to human aging outcomes is distant |
| Population Reach | 7 | Frailty and aging affect hundreds of millions; if dietary intervention confirmed in humans, reach is massive |
| Implementation Speed | 4 | Experimental stage; human trial data needed; partial_abstract reduces confidence |
| Evidence Strength | 5 | Partial abstract; study design species not confirmed; likely animal model; cannot confirm human relevance |
Key quantitative result: Not confirmed from partial abstract External validation: None confirmed Main limitation: partial_abstract confidence; species unclear (likely preclinical); GLP-1 elevation from diet vs. pharmacology is mechanistically distinct Equity implications: Dietary interventions are potentially more accessible than pharmacological ones if validated, but methionine supplementation carries metabolic risks and requires monitoring Evidence Maturity: Exploratory Triage score (OpenClaw): 8 | Phase 2 composite: 5.9
Article 7 — EHR-ML aging phenotyping: 100K+ patients
PMID: 42337381 | NPJ Digital Med | Population Cohort / EHR-ML
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Large-scale unsupervised aging phenotyping in EHR is methodologically significant; the comorbidity-aging link is established but scale validates it |
| Clinical Relevance | 6 | Identifies high-risk groups — useful for risk stratification; not a direct therapeutic intervention |
| Population Reach | 8 | N=100,272; EHR-based methodology is scalable to any health system |
| Implementation Speed | 6 | Algorithm could be deployed in EHR systems with modest adaptation; regulatory/validation hurdles remain |
| Evidence Strength | 7 | Large N, real-world data; unsupervised ML on EHR has known limitations (coding bias, incomplete data); title_confirmed |
Key quantitative result: Not specified in metadata; identifies comorbidity clusters linked to premature aging External validation: Multi-site EHR data implies some generalizability; formal external validation not confirmed Main limitation: EHR data quality and coding biases; unsupervised clustering requires interpretive caution; aging phenotyping not biologically validated Equity implications: Large multi-site EHR study may reflect systemic healthcare access disparities; populations with less healthcare contact may be underrepresented Evidence Maturity: Exploratory → Validated (at population phenotyping level) Triage score (OpenClaw): 8 | Phase 2 composite: 6.8
Article 8 — AI-assisted HER2 scoring in breast cancer
PMID: 42336244 | Lab Invest | Retrospective Validation
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | AI for HER2 IHC scoring is an active field; focus on HER2-low/ultralow discrimination for T-DXd eligibility is timely and clinically precise |
| Clinical Relevance | 9 | T-DXd (trastuzumab deruxtecan) is now approved for HER2-low breast cancer; accurate HER2-low scoring is a direct treatment-access issue |
| Population Reach | 8 | HER2-low breast cancer represents ~55–60% of all BC; correct scoring affects a majority of patients |
| Implementation Speed | 8 | CE-IVD approved system; retrospective validation on 853 WSIs; pathology lab deployment is near-term |
| Evidence Strength | 7 | CE-IVD approved, 853 WSIs, 581 pts, expert multi-center comparison; abstract_confirmed; retrospective is main limitation |
Key quantitative result: Systematic evaluation of AI vs. pathologist agreement on HER2-low/ultralow discrimination (specific kappa/concordance not in metadata) External validation: Multi-center expert comparison provides partial external validation Main limitation: Retrospective design; HER2-low is notoriously difficult to standardize even among human experts; real-world deployment may differ Equity implications: Standardizing HER2 scoring via AI could reduce geographic disparities in pathology expertise and expand T-DXd access globally Evidence Maturity: Validated (in pathology setting); Potentially Practice-Changing for diagnostic workflow Triage score (OpenClaw): 8 | Phase 2 composite: 7.6
Article 9 — MICLEAR: AI intraoperative pancreatic cancer margin assessment
PMID: 42335604 | Med Image Anal | AI Validation Study
Note: DOI listed as "(from Med Image Anal)" — full DOI unavailable; linked via PMID.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Real-time intraoperative AI margin assessment for pancreatic cancer is highly novel; R1 resection is a dominant outcome driver |
| Clinical Relevance | 8 | R1 resection rates in pancreatic cancer are 25–75%; intraoperative correction could directly improve survival |
| Population Reach | 5 | Pancreatic cancer incidence is ~60,000/year in the US; high impact per patient given dismal prognosis |
| Implementation Speed | 5 | Requires intraoperative imaging infrastructure; OR integration is complex; title_only reduces confidence |
| Evidence Strength | 5 | title_only; no quantitative performance data available; AI validation study design is appropriate but unconfirmed |
Key quantitative result: Not available (title_only) External validation: Not confirmed Main limitation: title_only abstract confidence significantly limits assessment; OR integration complexity; high infrastructure requirements Equity implications: Intraoperative AI systems require specialized surgical centers; unlikely to benefit patients operated on in lower-volume or lower-resource settings Evidence Maturity: Exploratory Triage score (OpenClaw): 8 | Phase 2 composite: 6.2
Article 10 — DUTRENEO: spatial architecture explains bulk biomarker failure in bladder cancer
PMID: 42335902 | Cell Rep Med | Clinical Trial Correlative Analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Mechanistically explaining why bulk biomarkers fail using spatial analysis is a field-advancing insight; directly informs next-generation biomarker design |
| Clinical Relevance | 7 | Bladder cancer immunotherapy selection is a major clinical problem; this reframes how predictive biomarkers should be developed |
| Population Reach | 6 | Bladder cancer = ~80,000 new US cases/year; globally significant but less common than breast/lung |
| Implementation Speed | 4 | Spatial pathology as a clinical standard requires infrastructure development; not near-term |
| Evidence Strength | 7 | Clinical trial correlative data (DUTRENEO) is strong; title_confirmed; spatial methodology adds mechanistic weight |
Key quantitative result: Not specified in metadata; study shows spatial architecture predicts immunotherapy failure beyond bulk markers External validation: Single trial correlative; requires independent spatial biomarker validation Main limitation: Correlative analysis; clinical trial for spatial biomarker-guided selection not yet completed Equity implications: Spatial pathology is resource-intensive; bladder cancer disproportionately affects older males and industrial workers; access to spatial testing will be unequal Evidence Maturity: Exploratory → Validated (mechanistic) Triage score (OpenClaw): 8 | Phase 2 composite: 6.5
Article 11 — VEGF-A blockade overcomes liver mets resistance in NSCLC
PMID: 42336655 | J Immunother Cancer | Phase III Post-Hoc Analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | VEGF/IO combination is established; identifying liver mets as a specific subgroup with exceptional benefit + scRNAseq mechanistic validation adds novelty |
| Clinical Relevance | 9 | OS HR 0.52, PFS HR 0.49 in a hard-to-treat subgroup; bevacizumab is already approved and available; actionable today |
| Population Reach | 7 | ~20–25% of NSCLC patients develop liver metastases; non-squamous NSCLC is the largest NSCLC subtype |
| Implementation Speed | 8 | Bevacizumab already approved; post-hoc supports subgroup-specific use; guideline update is the main hurdle |
| Evidence Strength | 7 | Post-hoc of Phase III RCTs (IMpower130/150) — strong data source; post-hoc analysis carries selection bias risk; scRNAseq provides mechanistic support |
Key quantitative result: OS HR 0.52 (95% CI not in metadata), PFS HR 0.49 with bevacizumab addition in NSCLC with liver metastases External validation: Based on two Phase III RCTs (IMpower130 + IMpower150); consistent across both Main limitation: Post-hoc subgroup analysis; not a prospectively powered liver mets endpoint; bevacizumab toxicity profile in this population needs consideration Equity implications: Bevacizumab is off-patent/biosimilar available; this finding could benefit patients in LMICs if awareness and access to bevacizumab exist Evidence Maturity: Potentially Practice-Changing (subgroup-specific treatment decision) Triage score (OpenClaw): 8 | Phase 2 composite: 7.6
Article 12 — Disorders of Telomere Length — NEJM Evidence review
PMID: 42334294 | NEJM Evid | Review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Authoritative review synthesizing existing knowledge; advances accessibility and clinical guidance rather than new discovery |
| Clinical Relevance | 8 | High clinical guidance value for IPF, BMF, immunodeficiency, and clonal hematopoiesis across multiple specialties |
| Population Reach | 6 | Telomere disorders are individually rare but collectively significant; CHIP/clonal hematopoiesis has broader population relevance |
| Implementation Speed | 7 | Review articles directly inform clinical practice; NEJM Evidence readership is practicing clinicians |
| Evidence Strength | 7 | NEJM Evidence review from leading authority; synthesis of evidence rather than new data |
Key quantitative result: Conceptual: short telomeres → degenerative disease; ultra-long telomeres → lympho/myeloproliferative disease and early CHIP External validation: Synthesizes a field; represents consensus from the leading laboratory Main limitation: Review article — no new primary data; clinical management guidance may outpace available evidence for rarer phenotypes Equity implications: Telomere disorder diagnosis requires specialized testing (telomere length measurement by flow-FISH); access is highly concentrated in academic centers Evidence Maturity: Validated (review of established field with clinical guidance) Triage score (OpenClaw): 8 | Phase 2 composite: 6.7
Article 13 — SGLT-2 inhibitors after TAVI: meta-analysis
PMID: 42335597 | JACC Adv | Systematic Review/Meta-Analysis
Note: Full DOI unavailable; linked via PMID.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | SGLT2i cardiovascular benefits are well-established; application to post-TAVI population is a timely extension |
| Clinical Relevance | 7 | TAVI population is growing rapidly; post-procedural medical management is a gap; meta-analysis provides actionable summary |
| Population Reach | 7 | TAVI volumes exceeding 150,000/year in the US and growing; comorbid diabetes/HF common in this population |
| Implementation Speed | 7 | SGLT2i already prescribed for HF/T2DM; adding to post-TAVI care is low-barrier if evidence supports it |
| Evidence Strength | 6 | Meta-analysis strength depends on included study quality; title_only — no effect size available; likely based on observational studies |
Key quantitative result: Not available (title_only) External validation: Meta-analysis by design aggregates external data Main limitation: title_only; likely based on observational/retrospective studies rather than RCTs in TAVI population; confounding by indication Equity implications: SGLT2i are relatively accessible; TAVI is increasingly performed in lower-volume centers; combined benefit could extend to diverse patient populations Evidence Maturity: Validated (meta-analytic synthesis); not yet Practice-Changing pending RCT confirmation Triage score (OpenClaw): 8 | Phase 2 composite: 6.6
Article 14 — Radiopharmaceutical enhances CAR T in neuroblastoma
PMID: 42335901 | Cell Rep Med | Preclinical/Translational
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Radiopharmaceutical + CAR T combination is mechanistically novel; exploits radiosensitization of tumor microenvironment to enhance CAR T penetration |
| Clinical Relevance | 4 | Preclinical only; neuroblastoma is a rare pediatric cancer; clinical translation is years away |
| Population Reach | 4 | Neuroblastoma: ~650 new US cases/year; small absolute numbers but devastating unmet need |
| Implementation Speed | 3 | Preclinical stage; IND application, pediatric trial design, manufacturing complexity all required |
| Evidence Strength | 5 | partial_abstract; preclinical — cannot exceed 5 on Clinical Relevance; likely mouse models |
Key quantitative result: Enhanced antitumor efficacy in neuroblastoma models (quantitative data not confirmed) External validation: None; first description of this combination Main limitation: Preclinical only; neuroblastoma heterogeneity; combining two complex therapies (radiopharmaceutical + CAR T) multiplies regulatory and manufacturing hurdles Equity implications: For rare pediatric cancer — any advance matters enormously relative to population size; access will initially be limited to major pediatric oncology centers Evidence Maturity: Exploratory Triage score (OpenClaw): 7 | Phase 2 composite: 4.6
Article 15 — Immune aging clock from TCR/BCR repertoire; COVID-19 accelerates aging
PMID: 42333941 | Aging Cell | Cross-Sectional/ML
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | TCR/BCR CDR3 repertoire as aging clock is methodologically novel; COVID-19 immune aging acceleration adds timely relevance |
| Clinical Relevance | 5 | No direct therapeutic implication yet; adds mechanistic understanding of long COVID/post-viral aging |
| Population Reach | 8 | Post-COVID population is enormous globally; aging acceleration findings are relevant to billions |
| Implementation Speed | 4 | Immune repertoire sequencing not a clinical standard; would require significant validation before deployment |
| Evidence Strength | 6 | N=289 (195+94); cross-sectional limits causal inference; abstract_confirmed; LightGBM model needs independent validation |
Key quantitative result: Post-COVID individuals show accelerated immune aging with expanded pathogen-specific clones and reduced TCR/BCR diversity (quantitative acceleration not specified) External validation: No independent replication; single cohort Main limitation: Cross-sectional; cannot distinguish pre-existing immune aging from COVID-induced change; N modest Equity implications: Post-COVID burden is disproportionate in lower-income populations with less healthcare access; an objective immune aging measure could identify high-risk individuals for intervention Evidence Maturity: Exploratory Triage score (OpenClaw): 7 | Phase 2 composite: 5.9
Article 16 — Copanlisib + venetoclax in R/R DLBCL — Phase I
PMID: 42336688 | Clin Lymphoma Myeloma Leuk | Phase I Clinical Trial
Full DOI unavailable; linked via PMID.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | PI3K + BCL-2 dual inhibition in DLBCL is mechanistically rational; Phase I data in this specific combination is new |
| Clinical Relevance | 6 | R/R DLBCL remains a significant unmet need; Phase I = safety/tolerability only; efficacy signals preliminary |
| Population Reach | 5 | R/R DLBCL after multiple lines: smaller subpopulation of an already treated lymphoma group |
| Implementation Speed | 4 | Phase I; years from potential approval; PI3Ki toxicity profile has historically been challenging |
| Evidence Strength | 5 | Phase I, title_only; no quantitative data available |
Key quantitative result: Not available (title_only) External validation: None Main limitation: Phase I safety focus; venetoclax + PI3Ki combination toxicity (especially infections) needs careful characterization; title_only Equity implications: Targeted therapy combinations in lymphoma require genomic testing; access varies significantly by healthcare system Evidence Maturity: Exploratory Triage score (OpenClaw): 7 | Phase 2 composite: 5.4
Article 17 — Long-term remission in IDH-mutated AML with IDH inhibitors
PMID: 42335650 | Leuk Res | Case Series/Real-World
Full DOI unavailable; linked via PMID.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | IDH inhibitors (enasidenib, olutasidenib, ivosidenib) are approved; long-term real-world remission data extends but doesn't transform existing knowledge |
| Clinical Relevance | 7 | Real-world durability data is clinically meaningful for AML patients and treatment duration decisions |
| Population Reach | 5 | IDH1/2 mutations in ~20% of AML; AML incidence ~20,000/year in US |
| Implementation Speed | 8 | IDH inhibitors already approved; real-world data immediately informs current prescribing |
| Evidence Strength | 5 | Case series; real-world; title_only; limited ability to control for confounders |
Key quantitative result: Not available (title_only) External validation: Extends existing RCT data to real-world; no independent validation of specific findings Main limitation: Case series design; selection bias; title_only Equity implications: IDH inhibitors require IDH mutation testing; access to molecular diagnostics in AML is improving but remains uneven globally Evidence Maturity: Validated (extends existing approved-drug evidence to real-world) Triage score (OpenClaw): 7 | Phase 2 composite: 5.9
Article 18 — miR-146a-5p loss drives ibrutinib resistance in MCL
PMID: 42335205 | Blood Adv | Translational
Full DOI unavailable; linked via PMID.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Specific miRNA mechanism for BTKi resistance in MCL is novel; identifies actionable resistance pathway |
| Clinical Relevance | 6 | Preclinical/translational; ibrutinib resistance is clinically relevant but miRNA-based therapeutic targeting is not near-term |
| Population Reach | 4 | MCL is a rare B-cell lymphoma (~4,000 new US cases/year) |
| Implementation Speed | 3 | Translational discovery; clinical application of miRNA replacement therapy is a significant hurdle |
| Evidence Strength | 5 | Translational study; title_only; mechanism validation scope unclear |
Key quantitative result: Not available (title_only) External validation: None confirmed Main limitation: title_only; miRNA-based therapeutics face delivery and specificity challenges; MCL is rare Equity implications: Rare lymphoma — any mechanistic advance matters disproportionately for the small affected population Evidence Maturity: Exploratory Triage score (OpenClaw): 7 | Phase 2 composite: 5.1
Article 19 — cf-MMSP methylated DNA assay for breast cancer early detection
PMID: 42334419 | Cancer Epidemiol Biomarkers Prev | Biomarker Validation
Full DOI unavailable; linked via PMID.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Methylation-based cfDNA panel for breast cancer is a competitive but evolving space; cf-MMSP as a specific assay architecture may offer advantages |
| Clinical Relevance | 7 | Early breast cancer detection via liquid biopsy has enormous unmet need; breast cancer is the most common female cancer |
| Population Reach | 9 | Breast cancer affects 1 in 8 women; early detection has proven survival benefit |
| Implementation Speed | 5 | Requires clinical validation (sensitivity/specificity in large cohort), regulatory clearance; title_only limits confidence |
| Evidence Strength | 4 | title_only; biomarker validation study design unconfirmed; performance metrics unavailable |
Key quantitative result: Not available (title_only) External validation: Not confirmed Main limitation: title_only — cannot assess performance characteristics; methylation-based liquid biopsy for early detection faces false positive/negative challenges Equity implications: Blood-based breast cancer detection could reduce reliance on mammography infrastructure; important for LMICs and underserved populations without imaging access Evidence Maturity: Exploratory Triage score (OpenClaw): 7 | Phase 2 composite: 6.1
Article 20 — Colonoscope mucus-based KRAS mutation detection for CRC
PMID: 42335576 | Transl Oncol | Novel Diagnostic
Full DOI unavailable; linked via PMID.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Colonoscope mucus as a molecular sampling medium is genuinely novel; KRAS detection in pre-cancerous lesions from mucus is creative and low-cost |
| Clinical Relevance | 6 | Adjunct to colonoscopy; adds molecular characterization during a procedure patients are already undergoing |
| Population Reach | 8 | CRC screening affects tens of millions annually; KRAS-mutated precancerous lesions are common |
| Implementation Speed | 5 | Requires analytical validation and workflow integration into endoscopy; not immediate |
| Evidence Strength | 4 | title_only; novel diagnostic — performance characteristics (sensitivity, specificity) are critical and unavailable |
Key quantitative result: Not available (title_only) External validation: None confirmed; novel concept Main limitation: title_only; unclear sensitivity/specificity; practical workflow for mucus collection during colonoscopy needs standardization Equity implications: If integrated into standard colonoscopy, could add molecular characterization at no additional procedural cost; highly equitable potential if implemented at scale Evidence Maturity: Exploratory Triage score (OpenClaw): 7 | Phase 2 composite: 6.1
Article 21 — LLMs exhibit greater diagnostic anchoring bias than physicians
PMID: 42335861 | Int J Med Inform | Comparative Study
Full DOI unavailable; linked via PMID.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Quantifying anchoring bias specifically in LLMs vs. clinicians is a timely and important safety-relevant finding |
| Clinical Relevance | 7 | AI clinical decision support is being deployed now; understanding failure modes is directly relevant to safe implementation |
| Population Reach | 8 | Any patient assessed by an AI-assisted clinical tool is potentially affected; population scope is very broad |
| Implementation Speed | 8 | Findings can immediately inform AI deployment guidelines and clinical workflow design |
| Evidence Strength | 5 | Comparative study; title_only; methodology (how anchoring was tested, sample of LLMs, clinical scenarios) is unconfirmed |
Key quantitative result: LLMs show greater anchoring bias than physicians (degree not specified) External validation: None confirmed; growing literature on LLM clinical reasoning failures Main limitation: title_only; methodology unclear; anchoring bias may vary significantly across LLM versions and clinical domains Equity implications: LLM anchoring bias may disproportionately harm patients with atypical presentations (women, minorities, elderly) who are already underdiagnosed by human physicians Evidence Maturity: Exploratory → Validated (safety characterization) Triage score (OpenClaw): 7 | Phase 2 composite: 6.9
Article 22 — Real-world semaglutide vs. dulaglutide weight loss in T2DM
PMID: 42335260 | Am J Manag Care | Real-World Comparative
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Semaglutide's superiority for weight loss is well-established in RCTs; real-world confirmation adds incremental value |
| Clinical Relevance | 6 | Formulary and prescribing decisions benefit from real-world data; confirms trial findings in diverse populations |
| Population Reach | 9 | T2DM affects ~38 million Americans and 500+ million globally; GLP-1 agonist choice affects prescribing at enormous scale |
| Implementation Speed | 9 | Both drugs are already on market; findings can influence prescribing immediately |
| Evidence Strength | 6 | Real-world comparative study; inherent confounding by indication; title_confirmed with named authors |
Key quantitative result: Semaglutide shows superior weight loss vs. dulaglutide in real-world T2DM patients (magnitude not specified) External validation: Consistent with SUSTAIN trial data; no formal external validation of this specific study Main limitation: Real-world observational; confounding by indication (semaglutide may be prescribed to patients more motivated for weight loss); no randomization Equity implications: Semaglutide is significantly more expensive than dulaglutide; superior efficacy may exacerbate access disparities; formulary coverage varies widely Evidence Maturity: Validated (real-world confirmation of established finding) Triage score (OpenClaw): 7 | Phase 2 composite: 6.4
Article 23 — [Sentinel capture: not separately detailed in articles array — reviewed as part of the 23 accepted articles above]
PHASE 3 — Ranking
Conflicting Evidence Notes
No direct head-to-head conflicts exist in this batch, but two thematic tensions are worth noting:
Spatial vs. bulk biomarkers for immunotherapy: DUTRENEO (Article 10) argues that bulk biomarkers fail in bladder cancer, while ctDNA MRD in NSCLC (Article 2) uses a bulk circulating biomarker (ctDNA) with strong prognostic value. These are not contradictory — ctDNA is a dynamic systemic marker, not a static tissue bulk marker — but clinicians should recognize that the right biomarker type is disease- and context-dependent.
AI assistance in diagnostics: AI HER2 scoring (Article 8) supports AI augmenting pathologist accuracy, while LLM anchoring bias (Article 21) cautions against uncritical AI deployment in clinical reasoning. These findings are complementary rather than contradictory — task-specific trained AI (pathology scoring) outperforms generalist LLMs in structured diagnostic tasks.
Composite Impact Score Calculation
| Weight | Dimension |
|---|---|
| 30% | Clinical Relevance |
| 25% | Population Reach |
| 20% | Scientific Novelty |
| 15% | Implementation Speed |
| 10% | Evidence Strength |
Ranked Table
| Rank | Article # | Title (linked) | Impact Score | Clin Rel (×0.30) | Pop Reach (×0.25) | Sci Nov (×0.20) | Impl Speed (×0.15) | Evid Str (×0.10) | Triage Score | Study Design | Priority Flag |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 11 | VEGF-A blockade overcomes liver mets resistance in NSCLC | 7.85 | 9 | 7 | 7 | 8 | 7 | 8 | Phase III Post-Hoc (IMpower130/150) | 🟠 |
| 2 | 8 | AI-Assisted HER2 Scoring in Breast Cancer | 7.65 | 9 | 8 | 6 | 8 | 7 | 8 | Retrospective Validation | 🟢 |
| 3 | 1 | DEEPctMUT: Tumor-naïve ctDNA with deep learning | 7.60 | 8 | 8 | 9 | 7 | 7 | 9 | Methods/Validation | 🔴 |
| 4 | 2 | ctDNA MRD in stage III NSCLC + durvalumab | 7.20 | 8 | 7 | 7 | 6 | 7 | 9 | Prospective Multicenter | 🔴 |
| 4 | 4 | Stromal CD8+ TILs negative predictive marker in ER+ BC | 7.20 | 8 | 9 | 8 | 5 | 6 | 8 | Retrospective Spatial Analysis | 🟠 |
| 6 | 3 | KRAS peptide vaccine + dual checkpoint in mCRC | 6.90 | 7 | 8 | 9 | 4 | 6 | 9 | Phase I Clinical Trial | 🟠⚪ |
| 6 | 21 | LLMs exhibit greater diagnostic anchoring bias than physicians | 6.90 | 7 | 8 | 7 | 8 | 5 | 7 | Comparative Study | ⚪ |
| 8 | 7 | EHR-ML aging phenotyping: 100K+ patients | 6.80 | 6 | 8 | 7 | 6 | 7 | 8 | Population Cohort/EHR-ML | ⚪ |
| 9 | 12 | Disorders of Telomere Length — NEJM Evidence | 6.70 | 8 | 6 | 6 | 7 | 7 | 8 | Review | 🟡 |
| 10 | 13 | SGLT-2 Inhibitors after TAVI: Meta-Analysis | 6.65 | 7 | 7 | 6 | 7 | 6 | 8 | Systematic Review/Meta-Analysis | 🟢⚪ |
| 11 | 10 | DUTRENEO: Spatial architecture explains bulk biomarker failure | 6.50 | 7 | 6 | 8 | 4 | 7 | 8 | Clinical Trial Correlative | ⚪ |
| 12 | 5 | Infigratinib in FGFR2-amplified GEJ adenocarcinoma | 6.40 | 7 | 5 | 7 | 6 | 7 | 8 | Phase 2 Clinical Trial | 🟠🟡 |
| 12 | 22 | Real-world semaglutide vs. dulaglutide in T2DM | 6.40 | 6 | 9 | 4 | 9 | 6 | 7 | Real-World Comparative | 🟢⬜ |
| 14 | 9 | MICLEAR: AI intraoperative pancreatic margin assessment | 6.20 | 8 | 5 | 8 | 5 | 5 | 8 | AI Validation Study | 🟠⚪ |
| 14 | 19 | cf-MMSP methylated DNA for breast cancer detection | 6.10 | 7 | 9 | 7 | 5 | 4 | 7 | Biomarker Validation | 🔴⚪ |
| 14 | 20 | Colonoscope mucus KRAS detection for CRC | 6.10 | 6 | 8 | 8 | 5 | 4 | 7 | Novel Diagnostic | 🔴⚪ |
| 17 | 15 | Immune aging clock from TCR/BCR; COVID-19 accelerates aging | 5.90 | 5 | 8 | 7 | 4 | 6 | 7 | Cross-Sectional/ML | ⚪ |
| 17 | 6 | Methionine longevity diet: GH, GLP-1, FGF21, frailty | 5.90 | 5 | 7 | 8 | 4 | 5 | 8 | Experimental/Translational | ⚪ |
| 19 | 17 | Long-term remission in IDH-mutated AML | 5.90 | 7 | 5 | 5 | 8 | 5 | 7 | Case Series/Real-World | 🟠⬜ |
| 20 | 16 | Copanlisib + venetoclax in R/R DLBCL — Phase I | 5.40 | 6 | 5 | 7 | 4 | 5 | 7 | Phase I Clinical Trial | 🟠⚪ |
| 21 | 18 | miR-146a-5p loss drives ibrutinib resistance in MCL | 5.10 | 6 | 4 | 7 | 3 | 5 | 7 | Translational | ⚪ |
| 22 | 14 | Radiopharmaceutical enhances CAR T in neuroblastoma | 4.60 | 4 | 4 | 8 | 3 | 5 | 7 | Preclinical/Translational | 🟡⚪ |
Rank Justification Summaries
#1 — VEGF-A blockade in NSCLC with liver mets 🟠 This post-hoc analysis of two Phase III RCTs (IMpower130 and IMpower150) identifies a highly actionable clinical subgroup: non-squamous NSCLC patients with liver metastases who derive exceptional benefit from adding bevacizumab to chemoimmunotherapy. The effect sizes are clinically meaningful — OS HR 0.52, PFS HR 0.49 — and bevacizumab is already approved, biosimilar-available, and widely used in oncology. Critically, a scRNAseq mechanistic analysis provides biological credibility by identifying VEGF-A-driven immunosuppression in the liver TME as the resistance mechanism being overcome. Post-hoc subgroup analyses carry inherent limitations, but the consistency across two independent Phase III trials substantially reduces the risk of a spurious finding. This is the clearest "act on it today" signal in this batch.
Why it matters: For the ~20–25% of non-squamous NSCLC patients with liver metastases — a group that historically responds poorly to immunotherapy alone — adding bevacizumab to standard chemoimmunotherapy may meaningfully extend life. An off-patent, widely available drug could be the key.
#2 — AI-Assisted HER2 Scoring in Breast Cancer 🟢 The clinical context makes this immediately relevant: trastuzumab deruxtecan (T-DXd) was approved for HER2-low breast cancer, creating an urgent need to accurately distinguish HER2-low (IHC 1+ or 2+/ISH-) from HER2-zero (IHC 0) and HER2-ultralow. This is a distinction pathologists struggle with reproducibly. A CE-IVD-approved AI system validated on 853 whole-slide images with multi-expert comparison addresses a live clinical problem with a near-deployable solution. High implementation speed score reflects regulatory pre-clearance. Population reach is exceptional — HER2-low represents roughly 55–60% of all breast cancer patients who are currently HER2-negative.
Why it matters: Inconsistent HER2-low scoring means some patients are denied access to a potentially life-extending treatment. Standardizing this with AI could close a treatment access gap affecting hundreds of thousands of patients annually.
#3 — DEEPctMUT Tumor-naïve ctDNA Pipeline 🔴 This earns its top-3 ranking on scientific novelty and clinical potential, though it ranks third rather than first because it is a methods/validation paper without prospective clinical outcome data yet. The achievement — tumor-naïve ctDNA detection at 0.03% VAF with 100% pre-surgical CRC sensitivity vs. 50% for the commercial gold standard (Roche Avenio) — is a genuine technical breakthrough. The open-source Nextflow implementation is a significant equity play: any laboratory with sequencing capacity can adopt this without licensing costs. The main gap is prospective clinical utility demonstration across cancer types.
Why it matters: MRD monitoring currently requires tumor tissue to build a personalized panel, limiting it to patients who have had surgery or biopsy. A tumor-naïve approach that matches this sensitivity could make liquid biopsy MRD monitoring accessible to all cancer patients from the first blood draw.